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Abstract: Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six 
thousand adults and almost three thousand children every year. Approximately 25% of the 
children  and  60%  of  the  adults  die  from  their  disease,  highlighting  the  need  for  new 
therapies  that  complement  rather  than  overlap  chemotherapy  and  bone  marrow 
transplantation. Immunotherapy is a class of therapies where toxicities and mechanisms of 
action do not overlap with those of chemotherapy. Because CD19 is a B cell- restricted 
membrane antigen that is expressed on the majority of pre-B tumor cells, a CD19-based 
immunotherapy is  being developed for ALL.  In this  study, the anti-tumor activities of 
immunotoxins  (ITs)  constructed by conjugating  a murine monoclonal  antibody  (MAb), 
HD37,  or  its  chimeric  (c)  construct  to  recombinant  ricin  toxin  A  chain  (rRTA)  were 
compared both in vitro using human pre-B ALL and Burkitt’s lymphoma cell lines and  
in vivo using a disseminated human pre-B ALL tumor cell xenograft model. The murine 
and  chimeric  HD37  IT  constructs  were  equally  cytotoxic  to  pre-B  ALL  and  Burkitt’s 
lymphoma cells in vitro and their use in vivo resulted in equivalent increases in survival of 
SCID mice with human pre-B ALL tumors when compared with control mice.  
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1. Introduction 
Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six thousand adults and 
almost  three  thousand  children  every  year.  Despite  the  development  of  more  sensitive  detection 
methods  and  more  effective  treatment  options,  approximately  25%  of  children  [1,2]  and  60%  of  
adults [1,3] with pre-B ALL are not cured by conventional therapy. First line chemotherapy consists of 
cyclophosphamide, vincristine, adriamycin and dexamethasone (CVAD) [4]. CVAD is associated with 
acute  and  chronic  toxicities  including  myelosuppression,  cardiac  toxicity,  nausea,  vomiting,  
infections, etc. [5]. If the disease relapses, doses of chemotherapy are increased, sometimes resulting in 
short term responses and always resulting in increased toxicity. Patients who relapse 2
nd line therapy 
often  undergo  allergenic  or  autologous  bone  marrow  transplantation,  which  is  associated  with 
additional toxicity and sometimes, but rarely, durable responses. Effective MAb therapy for pre-B 
ALL  would  be  a  significant  advantage  over  chemotherapy  or  radiotherapy  because  MAbs  would 
selectively kill the leukemic cells, resulting in less toxicity. In addition, toxicity from a MAb- based 
therapy is unlikely to overlap toxicity from traditional chemotherapy and could thus be combined with 
chemotherapy or used as consolidation therapy immediately following chemotherapy without risk of 
exacerbating chemotherapy induced toxicity. 
Several MAb- based therapies have been approved by the Food and Drug Administration (FDA) for 
lymphoma or leukemia. Three MAb-based therapies, all of which target CD20, have been approved for 
the treatment of non-Hodgkin’s lymphoma. One of these is unconjugated, and two are conjugated to 
radionuclides [6]. CD20 is a B cell specific transmembrane protein; it is expressed only on mature B 
lymphocytes and not on pro-B or pre-B cells [7,8] and therefore would not be effective in pre-B ALL. 
Campath, an anti-CD52 MAb is approved for use in B cell chronic lymphocytic leukemia but would 
also not be effective in pre-B cell ALL. Furthermore, there are no MAb-based therapies that have been 
FDA-approved for the treatment of childhood malignancies. These therapies confirm the potential of 
MAb based therapies for treatment of leukemia and lymphoma. 
CD19 is also a transmembrane glycoprotein that is restricted to B cell expression in both mouse and 
humans  [9].  It  is  expressed  on  B  cells  following  the  differentiation  of  pluripotent  stem  cell  into 
committed B lymphocytes and is expressed until terminal differentiation of lymphocytes into plasma 
cells [10]. Thus, CD19 is expressed on pre-B cells (including pre-B ALL cells) while CD20 is not, and 
as  compared to  CD20, CD19 expression persists  longer on B cells  during their maturation. More 
lymphoid malignancies express CD19 than CD20 [10,11]. In addition, unlike CD20, CD19 is rapidly 
internalized [10,12] which makes it a more attractive target for an IT.  
One of the most commonly used toxins for chemical construction of ITs is RTA. Its native form is 
N-glycosylated and hence mannose and fructose receptors on liver cells can recognize and bind the 
RTA protein of iTs, thus shortening their half lives and causing liver damage. For this reason, RTA has 
been  chemically  deglycosylated  (dgRTA)  before  its  conjugation  [13].  To  avoid  the  problem  of 
working  with  ricin,  a  recombinant  RTA  devoid  of  all  carbohydrate  moieties  is  now  expressed  in 
bacteria [14]. Despite some difference in their structure, the function and the biological activities of 
dgRTA and rRTA are the same [15]. 
In vitro, the anti-CD19 IT, HD37-dgRTA, is effective in killing Burkitt’s lymphoma cell lines,  
pre-B ALL cell lines and leukemic cells from children with pre-B ALL [16,17]. In vivo, HD37-dgRTA Toxins 2011, 3                   
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prolonged the survival of SCID mice that had been injected with human non-Hodgkin’s lymphoma 
(NHL) cells or pre-B ALL cells compared with the survival of control mice injected with saline or an 
isotype-matched control IT [18–21]. Treatment with a mixture of HD37-dgRTA and RFB4-dgRTA, an 
anti CD22 IT, was more effective than either IT alone [21].  
The anti-tumor efficacy of HD37-dgRTA in adults with NHL was demonstrated in Phase I clinical 
trials. In addition, HD37-dgRTA was used in combination with RFB4-dgRTA in children with pre-B 
ALL [22–24]. Three of 17 children experienced complete remissions and the combination was well 
tolerated.  Although  these  studies  held  promising  results  for  the  anti-tumor  efficacy  of  the  ITs, 
approximately 25–30% of patients made human anti-mouse antibodies (HAMA) against HD37, which 
prevented  additional  courses  of  treatment  in  those  patients.  Since  many  of  these  patients  had 
experienced  significant  decreases  in  tumor  burden,  the  inability  to  administer  repeat  courses  of 
treatment was clinically very significant.  
In this study our goals were to construct a chimeric HD37 MAb (cHD37), containing the variable 
regions of the murine HD37 and the human constant IgG1κ region, and then to construct an IT by 
conjugating cHD37 to rRTA (cHD37-rRTA). This IT should be less immunogenic in humans although 
there might  still be a response to  RTA. We compared the  in  vitro activity of cHD37-rRTA  with  
HD37-rRTA using human Burkitt’s lymphoma and pre-B ALL cell lines. They were equally cytotoxic 
in vitro. We then compared the in vivo activity of cHD37-rRTA with HD37-rRTA in SCID mice 
xenografted with a human pre-B ALL cell line (SCID/NALM-6 mice). The anti-tumor activity of 
cHD37-rRTA and HD37-rRTA were equally effective in prolonging the survival of SCID/NALM-6 
mice as compared to PBS and an isotype-matched control IT.  
2. Materials and Methods 
2.1. Construction and Expression of the cHD37 MAb 
The heavy and light chains of cHD37 were generated using vectors containing the human IgG1 and 
kappa constant region domains, pAH4604 and pAG4622. These were a generous gift from Dr. Sherrie 
Morrison [25]. The heavy and light variable domains of HD37 were separately amplified by PCR using 
cDNA prepared from HD37 hybridoma cells with primers that annealed in their respective inferred leader 
peptides and their constant domains. After verifying the accuracy of the variable domain genes, primer 
pairs A/B and C/D were used to amplify HD37 genes for insertion into antibody expression vectors. The 
primers are as follows: A, 5’-GGGTCTAGATATCCACCATGGGATGGAGCTTGATCTTTCTCTT-3’; 
B, 5’-GTCTAGGAATTCGCTAGCTGAGGAGACGGTGACTGAGG-3’;  C,  5’-GGGTCTAGATAT 
CCACCATGGAGACAGACACACTCCTGCTATGGG-3’;  and  D,  5’-GTCTAGGAATTCGTCGAC 
TTACGTTTGATTTCCAGCTTGGTGC-3’.  
The heavy and light chain constructs were co-transfected into SP2/0-AG14 cells (ATCC, Manassas, 
VA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Stable transfectants were selected using 
Dulbecco’s Minimal Essential medium (DMEM) medium (Sigma, St. Louis, MO) supplemented with 
10% heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT), 2 mM glutamate, and 10 mM  
L-histidinol (Sigma, St. Louis, MO). Positive clones were screened using human Ig-specific enzyme 
linked immunosorbent assays (ELISAs). Toxins 2011, 3                   
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2.2. Purification of cHD37 
Proteins in the cell culture supernatant were precipitated at 4 ° C with ammonium sulfate at 50% 
saturation, dissolved in distilled water and dialyzed overnight against PBS, pH 7.5. The dialysate was 
affinity-purified on Protein  G-Sepharose (Amersham Biosciences,  Piscataway, NJ), and the bound 
proteins were eluted with 0.1 M Glycine-HCl-NaN3 buffer, neutralized and dialyzed overnight against 
PBS, pH 7.5. The dialysate was concentrated, filter-sterilized, and stored at 4 ° C. 
2.3. Preparation of ITs 
HD37 and cHD37 were chemically conjugated to either dgRTA [16,26] or rRTA [15] using the 
linker  4-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyldithio)-toluene  (SMPT)  (Pierce,  Rockford, 
IL)  and  purified  as  previously  described  [27,28].  Briefly,  SMPT  dissolved  in  dimethylformamide 
(Sigma) was added to a solution of antibody (5 mg/mL) to give a final molar ratio of linker to antibody 
of 5:1. After incubation for 1 h at room temperature, the solution was passed through a column of  
Sephadex  G-25  (Amersham  Biosciences)  in  PBS.  The  derivatized  protein  contained  1.5–2.5  
α-methyl-α(2-pyridyldithio)toluoyl  groups  as  determined  by  spectrophotometry.  The  derivatized 
protein  was  then  mixed  with  freshly  reduced  rRTA  using  0.5  mg  rRTA  per  mg  of  MAb,  and 
maintained under sterile conditions for 36 h at room temperature while the reaction proceeded. The 
resulting IT was purified by affinity chromatography, first by binding the IT and unconjugated rRTA 
onto Blue Sepharose (Amersham Biosciences) in 0.05 M phosphate buffer, at pH 7.0. Then, free rRTA 
and  IT  were  eluted  with  1  M  NaCl  in  0.05  M  phosphate  buffer,  pH  7.0.  The  eluate  was 
chromatographed on Superdex 200 (Amersham Biosciences) in PBS. The first peak, which contained 
the IT, was collected, concentrated by ultrafiltration, sterilized by filtration and stored in aliquots at  
4  °C .  HD37-dgRTA  and  RFT5-dgRTA  (isotype-match  control  IT)  were  constructed  in  the  same 
manner using dgRTA instead of rRTA as previously described [16,26]. 
2.4. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The purity and molecular weights of the ITs were analyzed by 4–15% SDS-PAGE (Amersham 
Biosciences) using a PhastSystem™ (Amersham Biosciences). The gel was stained with PhastGel Blue 
R (Amersham Biosciences). 
2.5. Cells 
Cell lines include the CD19-expressing human Burkitt’s lymphoma cell lines: Daudi, Namalwa, and 
Raji; the human pre-B ALL cell line: NALM-6; and the human FcγRI-expressing cell line: U937. Cells 
were obtained from ATCC (Manassas, VA) and maintained in culture by serial passages in complete 
medium consisting of RPMI-1640 (Sigma) supplemented with 10% heat-inactivated FBS and 2 mM  
L-glutamine. 
2.6. Antigen-Binding Activity of ITs and MAbs 
One million cells were incubated with dilutions of ITs or MAbs (0.01–10 g/mL) followed by 
FITC-labeled  goat  anti-human  Ig  (GAHIg)  under  saturating  conditions  and  analyzed  on  a Toxins 2011, 3                   
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FACSCalibur (Becton Dickinson, San Jose, CA). The percentage of positive cells was plotted against 
the concentration of IT or MAb. 
2.7. [
3H]Thymidine Incorporation 
Tumor cells cultured in complete medium (5 ×  10
4 cells/100 μL) were plated in 96-well plates and 
incubated for 48 h at 37 °C with 100 μL of different concentrations of the ITs (ranging from 10
−8 to  
10
−13  M)  or  controls.  The  cells  were  then  pulsed  for  4  h  at  37  ° C  with  0.5  μCi  [
3H]thymidine 
(Amersham Biosciences), harvested and counted in a liquid scintillation spectrometer. The percentage 
reduction in [
3H]thymidine incorporation at different concentrations of ITs compared with thymidine 
incorporation in the cells to which controls were added was used to quantitate the cytotoxic effect 
(expressed as the IC50). 
2.8. Therapy of SCID/NALM-6 Mice 
Six to nine weeks old female SCID-SCRF-M mice (Taconic, Germantown, NY) were inoculated 
intravenously in the tail veins with 5 ×  10
6 NALM-6 cells in 0.1 mL sterile PBS, pH 7.4. After  
24  h,  groups  of  5  mice  were  injected  intraperitoneally  with  PBS  or  different  ITs  in  four  equal 
injections on days 1 to 4 after tumor inoculation. The treatment groups were as follows: (1) PBS,  
pH 7.4; (2) 4.7 μg/g HD37-rRTA; (3) 4.7 μg/g cHD37-rRTA; (4) 4.7 μg/g HD37-dgRTA; and (5)  
4.7 μg/g RFT5-dgRTA. The dose for the IT treatment was 40% of the LD50 of HD37-dgRTA based on 
previous studies [17,20]. Mice were followed daily and were sacrificed at the onset of paralysis, a 
clinical symptom which accurately predicts death. The mean paralysis time (MPT) was taken as the 
end  point. MPT  curves  were  compared  using  the  Wilcoxon  matched-pairs  log-rank  test  and  were 
considered to be significantly different when p < 0.05. 
3. Results 
3.1. Construction, Expression and Purification of cHD37 
cHD37 was expressed and purified to homogeneity. The purity and molecular weight were assessed 
by SDS-PAGE. There were no differences in the purity or the molecular weight of the recombinant 
construct and the murine HD37 used as a control (Figure 1). 
3.2. Preparation of ITs 
ITs were constructed by coupling the recombinant or murine HD37 MAbs to rRTA or dgRTA using 
the heterobifunctional  linker, SMPT [27,28]. This linker generates one  or more hindered disulfide 
bonds between the MAb and RTA. SDS-PAGE densitometric analysis of the ITs showed that >60% of 
the protein was found in the major band at 180 kDa (one molecule of IgG and one molecule of rRTA). 
In addition there were two minor bands (~30% and 10%) corresponding to ITs with two or three 
molecules  of  rRTA  or  dgRTA  per  molecule  of  IgG  (210  and  240  kDa,  respectively)  for  the  
ITs (Figure 2). 
 Toxins 2011, 3                   
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Figure 1. SDS-PAGE analysis of the purified cHD37 and HD37 MAbs. A 4–15% gradient 
gel  was  performed  under  non-reducing  (lanes  2  and  3)  and  reducing  (lanes  4  and  5) 
conditions. Lane 1: molecular weight markers; lanes 2 and 4: murine HD37; lanes 3 and 5: 
cHD37. This is one representative gel from three experiments.  
 
Figure  2.  SDS-PAGE  analysis  of  the  purified  cHD37-rRTA  and  HD37-rRTA  ITs. 
A 4–15% gradient gel was performed under non-reducing conditions. Lane 1, molecular 
weight markers; lane 2: cHD37-rRTA; lane 3: HD37-rRTA; lane 4: HD37-dgRTA. This is 
one representative gel from three experiments. 
 
3.3. Binding of ITs and MAbs to CD19
+ Cells  
To  determine  whether  chimerization  of  HD37  affected  its  binding  to  target  cells,  HD37,  
HD37-rRTA, cHD37, and cHD37-rRTA were evaluated for binding to CD19
+ cells by flow cytometry 
(Figure 3). All four compounds bound equally well in a dose dependent manner to NALM-6, Daudi, 
Namalwa and Raji cells. Neither the isotype-matched control myeloma protein, MOPC-21 nor the  
control IT, RFT5-dgRTA, bound to the cells. These results indicate that chimerization of HD37 did not 
affect the binding of the MAb to CD19. Toxins 2011, 3                   
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Figure 3. Binding of HD37 IT and MAb constructs to CD19
+ cell lines. The ability of the 
ITs and MAbs to bind CD19
+ (A) NALM-6, (B) Daudi, (C) Namalwa, and (D) Raji cells 
was  assessed  by  flow  cytometry.  Diamonds:  RFT5-dgRTA;  open  circles:  
MOPC-21(control);  squares:  cHD37;  circles:  HD37;  triangles:  HD37-rRTA;  inverted 
triangles: cHD37-rRTA. Data represent means ±  SD of three experiments. 
   
   
3.4. Cytotoxicity of the ITs in Vitro 
Cytotoxicity of HD37-rRTA, cHD37-rRTA and the control IT, RFT5-dgRTA, to human pre-B ALL 
NALM-6 cells is shown in Figure 4A. Both HD37 IT constructs killed the cells with equal efficiency 
(IC50 of HD37-rRTA = 4 ×  10
−10 M; IC50 of cHD37-rRTA = 3 ×  10
−10 M), while the control IT had no 
effect. Cytotoxicity was also assessed in human Burkitt’s lymphoma cell lines, and both HD37 ITs 
killed Daudi (IC50 of HD37-rRTA = 7 ×  10
−11 M; IC50 of cHD37-rRTA = 6 ×  10
−11 M), Namalwa  
(IC50  of  HD37-rRTA  =  5  ×   10
−10  M;  IC50  of cHD37-rRTA  =  3.5  ×   10
−10  M),  and Raji  (IC50  of  
HD37-rRTA = 10
−10 M; IC50 of cHD37-rRTA = 10
−10 M) cell lines equally well (Figure 4B–D). These 
results indicate that the chimerization of the MAb did not affect the cytotoxicity of the IT that it was  
prepared with. 
(A)  (B) 
(C)  (D) Toxins 2011, 3                   
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Figure 4. Cytotoxicity of HD37 IT constructs on CD19
+ cells lines.The cytotoxicity of the 
HD37  IT  constructs  were  evaluated  by  [
3H]thymidine  incorporation  on  (A)  NALM-6,  
(B) Daudi, (C) Namalwa, and (D) Raji cells. Triangles: RFT5-dgRTA; squares: cHD37-
rRTA; circles: HD37-rRTA. 
   
   
3.5. Therapeutic Efficacy of the ITs in SCID/NALM-6 Mice 
Since HD37-rRTA and cHD37-rRTA exhibited cytotoxic activity against NALM-6 cells in vitro, 
and  previous  studies  using  SCID/NALM-6  mice  demonstrated  anti-tumor  activity  of  
HD37-dgRTA [18], SCID mice xenografted with NALM-6 cells were chosen to compare the in vivo 
anti-tumor activity of HD37-dgRTA, HD37-rRTA and cHD37-rRTA. SCID mice were injected with  
5 ×  10
6 NALM-6 tumor cells on day 0. Groups of 5 mice were then treated with 4.7 μg/g of IT on days 
1–4 post tumor inoculation. As compared to PBS (p < 0.006), the RFT5-dgRTA control (p < 0.017), 
all three anti-CD19 ITs significantly extended the MPT of SCID/NALM-6 mice and however, there 
was no difference in the MPT of the groups treated with HD37-dgRTA, HD37-rRTA, or cHD37-rRTA  
(p < 0.233) (Figure 5). These results show that chimerization of the HD37 has not affected the in vivo 
potency of the IT against NALM-6 tumors in SCID mice.  
 
 
(A)  (B) 
(C)  (D) Toxins 2011, 3                   
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Figure 5. Therapeutic efficacy of the HD37 IT constructs in SCID mice with NALM-6 
tumor cell xenografts. SCID/NALM-6 mice were treated on days 1 through 4 after tumor 
inoculation with the following ITs (5 mice per treatment group): open circles: PBS; open 
squares: RFT5-dgRTA; inverted triangles: HD37-rRTA; diamonds: cHD37-rRTA; circles: 
HD37-dgRTA. Arrows indicate treatment days (1–4). The  graphs  are  representative  of 
three separate experiments.  
 
4. Discussion 
Previous studies have shown that an anti-CD19 IT, HD37-dgRTA, is effective in prolonging the 
survival  of  SCID  mice  xenografted  with  human  pre-B  ALL  or  NHL  tumors  either  alone  or  in 
combination with an anti-CD22 IT and/or chemotherapy [18–21]. Phase I clinical trials in humans with 
lymphoma and leukemia have demonstrated the anti-tumor efficacy of HD37-dgRTA either alone or in 
combination with an anti-CD22 IT [22–24].  
The goal of this study was to construct cHD37 MAb and cHD37-rRTA IT and to compare the  
anti-tumor activity of cHD37-rRTA with HD37-rRTA. Our study showed that chimerization of HD37 
did not affect its binding activity, its in vitro cytotoxic activity, or its in vivo anti-tumor efficacy. 
Studies in clinical trials in humans will determine whether the cHD37-rRTA will be well tolerated in 
patients and whether HAMA will be generated. 
In conclusion, our results indicate that the anti-tumor activity of a chimeric, recombinant anti-CD19 
IT, cHD37-rRTA, is equally as efficacious as that of the murine IT, HD37-dgRTA and HD37-rRTA  
in vitro and in SCID/NALM-6 mice. Further studies in patients will be necessary to determine optimal 
treatment regimens and whether this IT is less immunogenic in humans.  
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